MX2016010427A - Compuestos tetrahidropiridopirimidina novedoso o una sal del mismo. - Google Patents

Compuestos tetrahidropiridopirimidina novedoso o una sal del mismo.

Info

Publication number
MX2016010427A
MX2016010427A MX2016010427A MX2016010427A MX2016010427A MX 2016010427 A MX2016010427 A MX 2016010427A MX 2016010427 A MX2016010427 A MX 2016010427A MX 2016010427 A MX2016010427 A MX 2016010427A MX 2016010427 A MX2016010427 A MX 2016010427A
Authority
MX
Mexico
Prior art keywords
salt
tetrahydropyridopyrimidine compound
compound
novel
novel tetrahydropyridopyrimidine
Prior art date
Application number
MX2016010427A
Other languages
English (en)
Other versions
MX360496B (es
Inventor
Masanori Asai
Shinichi Aoki
Yamanaka Hiroyoshi
Minamiguchi Kazuhisa
Okajima Shigeo
Asai Takahiro
Dohi Suguru
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016010427A publication Critical patent/MX2016010427A/es
Publication of MX360496B publication Critical patent/MX360496B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Proporcionar un compuesto que tiene una actividad inhibidora para un receptor de andrógenos; un compuesto tetrahidropiridopirimidina representado por la siguiente fórmula general (I) o una sal farmacéuticamente aceptable del mismo (en la fórmula, X y R son como se definen en la especificación). (ver Fórmula).
MX2016010427A 2014-05-29 2015-05-28 Compuestos tetrahidropiridopirimidina novedoso o una sal del mismo. MX360496B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014111147 2014-05-29
PCT/JP2015/065425 WO2015182712A1 (ja) 2014-05-29 2015-05-28 新規テトラヒドロピリドピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2016010427A true MX2016010427A (es) 2016-09-22
MX360496B MX360496B (es) 2018-11-05

Family

ID=54699035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010427A MX360496B (es) 2014-05-29 2015-05-28 Compuestos tetrahidropiridopirimidina novedoso o una sal del mismo.

Country Status (21)

Country Link
US (3) US9662333B2 (es)
EP (1) EP3150599B1 (es)
JP (1) JP5851663B1 (es)
KR (1) KR101708604B1 (es)
CN (1) CN106103434B (es)
AU (2) AU2015268494B2 (es)
BR (1) BR112016027691B1 (es)
CA (1) CA2941668C (es)
DK (1) DK3150599T3 (es)
ES (1) ES2703168T3 (es)
HU (1) HUE041645T2 (es)
MX (1) MX360496B (es)
MY (1) MY162886A (es)
PH (1) PH12016501252B1 (es)
PL (1) PL3150599T3 (es)
PT (1) PT3150599T (es)
RU (1) RU2636310C1 (es)
SG (1) SG11201604954YA (es)
TR (1) TR201819419T4 (es)
TW (1) TWI585087B (es)
WO (1) WO2015182712A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2636310C1 (ru) 2014-05-29 2017-11-22 Тайхо Фармасьютикал Ко., Лтд. Новое тетерагидропиримидиновое соединение или его соль
US10370372B2 (en) 2015-11-27 2019-08-06 Taiho Pharmaceutical Co., Ltd. Fused pyrimidine compound or salt thereof
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
SI3546456T1 (sl) * 2016-11-28 2022-04-29 Teijin Pharma Limited Kristal derivata pirido(3,4-D)pirimidina ali njegovega solvata
CN106727588A (zh) * 2016-11-30 2017-05-31 顾克斌 一种治疗急性肺损伤的药物组合物
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用
MA54311A (fr) 2018-11-26 2022-03-02 Taiho Pharmaceutical Co Ltd Procédé thérapeutique et prophylactique contre une tumeur pouvant être traitée par endocrinothérapie faisant appel à une utilisation combinée d'un inhibiteur des récepteurs du facteur de croissance des fibroblastes et d'une endocrinothérapie
WO2021058017A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use
TW202304450A (zh) * 2021-03-31 2023-02-01 日商大鵬藥品工業股份有限公司 以雄性素受體拮抗劑進行的轉移性去勢抗性前列腺癌患者之治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002088073A (ja) 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
TW200530235A (en) * 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
KR20070112775A (ko) * 2005-01-10 2007-11-27 아카디아 파마슈티칼스 인코포레이티드 선택적인 안드로겐 수용체 조절자로서의 아미노페닐 유도체
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007019083A1 (en) * 2005-08-04 2007-02-15 Janssen Pharmaceutica N.V. Pyrimidine compounds as serotonin receptor modulators
JP5555236B2 (ja) 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター
RU2636310C1 (ru) * 2014-05-29 2017-11-22 Тайхо Фармасьютикал Ко., Лтд. Новое тетерагидропиримидиновое соединение или его соль

Also Published As

Publication number Publication date
AU2017219032B2 (en) 2018-11-08
US10300067B2 (en) 2019-05-28
CA2941668C (en) 2019-04-16
AU2015268494B2 (en) 2017-06-08
JP5851663B1 (ja) 2016-02-03
CA2941668A1 (en) 2015-12-03
WO2015182712A1 (ja) 2015-12-03
EP3150599A4 (en) 2017-11-22
CN106103434A (zh) 2016-11-09
AU2015268494A1 (en) 2016-08-18
PT3150599T (pt) 2018-12-28
AU2017219032A1 (en) 2017-09-14
MX360496B (es) 2018-11-05
DK3150599T3 (en) 2019-01-14
EP3150599A1 (en) 2017-04-05
US20160244444A1 (en) 2016-08-25
US20180161331A1 (en) 2018-06-14
JPWO2015182712A1 (ja) 2017-04-20
HUE041645T2 (hu) 2019-05-28
MY162886A (en) 2017-07-20
EP3150599B1 (en) 2018-10-24
TR201819419T4 (tr) 2019-01-21
PH12016501252A1 (en) 2016-08-15
US9889136B2 (en) 2018-02-13
BR112016027691B1 (pt) 2019-07-02
CN106103434B (zh) 2019-05-10
SG11201604954YA (en) 2016-07-28
ES2703168T3 (es) 2019-03-07
US9662333B2 (en) 2017-05-30
BR112016027691A2 (pt) 2017-08-15
RU2636310C1 (ru) 2017-11-22
PH12016501252B1 (en) 2016-08-15
US20160310496A1 (en) 2016-10-27
KR101708604B1 (ko) 2017-02-20
TWI585087B (zh) 2017-06-01
KR20160095660A (ko) 2016-08-11
PL3150599T3 (pl) 2019-03-29
TW201617344A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
MA39749A (fr) Dérivés de pipéridine-dione
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
MX2018006148A (es) Inhibidores de cxcr2.
WO2016011390A8 (en) Irak4 inhibiting agents
EP3121175A4 (en) 1,3-benzodioxole derivative
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EP4219526A3 (en) Method for preparing amg 416
EP3135668A4 (en) Novel disubstituted 1, 2, 4-triazine compound
MX365494B (es) Procedimiento de compuesto antifungico.
MX369357B (es) Procedimiento de compuesto antifungico.
AU2015352440B2 (en) Compounds
PH12018500903A1 (en) Pyranodipyridine compound
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2015008829A (es) Momelotinib deuterado.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2016016127A (es) Formas cristalinas.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX2020006006A (es) Polimorfos cristalinos de {(2s,3r)-1-[(2s)-2-{5-[(2r,5r)-1-{3,5-di fluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}-5-(6-fluoro-2-{( 2s)-1-[n-(metoxicarbonil)-o-metil-l-treonil]pirrolidin-2-il}-1h-b enzimidazol-5-il)pirrolidin-2-il]-6-fluoro-1h-benzimidazol-2-il}p irrolidin-1-il]-3-metoxi-1-oxobutan-2-il}carbamato de metilo.
IN2014MU00859A (es)
MX2015012610A (es) Pacritinib deuterizado.
EP3177280A4 (en) Synthesis of 2,2,2-trifluoroethanethiol
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
TN2014000522A1 (fr) لوح مدرسي بوجهين

Legal Events

Date Code Title Description
FG Grant or registration